Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
SPRY ARS Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: SPRY
Price (delayed)
$13.6
Market cap
$1.34B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.17
Enterprise value
$1.37B
Silverback Therapeutics, Inc. operates as a biotechnology company. The Company discovers and develops novel and proprietary ImmunoTAC technology, which is designed to create potent therapeutic molecules that can be systemically
Highlights
The net income has soared by 69% YoY
SPRY's EPS has surged by 67% year-on-year
ARS Pharmaceuticals's equity has decreased by 11% from the previous quarter but it has increased by 2.3% YoY
ARS Pharmaceuticals's quick ratio has plunged by 83% YoY and by 25% from the previous quarter
ARS Pharmaceuticals's gross margin has decreased by 2.1% YoY
Key stats
What are the main financial stats of SPRY
Market
Valuations
Earnings
Shares outstanding
98.21M
Market cap
$1.34B
Enterprise value
$1.37B
Price to earnings (P/E)
N/A
Price to book (P/B)
5.83
Price to sales (P/S)
13.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.06
Revenue
$97.12M
Gross profit
$95.05M
Operating income
-$27.07M
Net income
-$15.65M
EBIT
-$15.36M
EBITDA
-$15.01M
Free cash flow
-$21.06M
Per share
Balance sheet
Liquidity
EPS
-$0.17
EPS diluted
-$0.17
Free cash flow per share
-$0.21
Book value per share
$2.33
Revenue per share
$0.99
TBVPS
$3.26
Total assets
$327.32M
Total liabilities
$98.34M
Debt
$69.46M
Equity
$228.97M
Working capital
$276.24M
Debt to equity
0.3
Current ratio
11
Quick ratio
10.32
Net debt/EBITDA
-1.97
Margins
Efficiency
Dividend
EBITDA margin
-15.5%
Gross margin
97.9%
Net margin
-16.1%
Operating margin
-27.9%
Return on assets
-5.6%
Return on equity
-6.9%
Return on invested capital
-6.2%
Return on capital employed
-5.1%
Return on sales
-15.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SPRY stock price
How has the ARS Pharmaceuticals stock price performed over time
Intraday
11.52%
1 week
1.19%
1 month
-8.6%
1 year
49.45%
YTD
28.91%
QTD
8.11%
Financial performance
How have ARS Pharmaceuticals's revenue and profit performed over time
Revenue
$97.12M
Gross profit
$95.05M
Operating income
-$27.07M
Net income
-$15.65M
Gross margin
97.9%
Net margin
-16.1%
ARS Pharmaceuticals's net margin has soared by 100% YoY
ARS Pharmaceuticals's operating margin has surged by 100% YoY
The net income has soared by 69% YoY
The company's operating income has surged by 56% YoY
Price vs fundamentals
How does SPRY's price correlate with its fundamentals
Growth
What is ARS Pharmaceuticals's growth rate over time
Valuation
What is ARS Pharmaceuticals stock price valuation
P/E
N/A
P/B
5.83
P/S
13.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.06
SPRY's EPS has surged by 67% year-on-year
The price to book (P/B) is 108% higher than the 5-year quarterly average of 2.8 and 14% higher than the last 4 quarters average of 5.1
ARS Pharmaceuticals's equity has decreased by 11% from the previous quarter but it has increased by 2.3% YoY
The price to sales (P/S) is 98% lower than the last 4 quarters average of 555.0
SPRY's revenue is up by 9% since the previous quarter
Efficiency
How efficient is ARS Pharmaceuticals business performance
SPRY's return on sales has surged by 100% year-on-year
SPRY's return on invested capital has surged by 80% year-on-year
The company's return on assets has surged by 73% YoY
SPRY's ROE has soared by 67% YoY
Dividends
What is SPRY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SPRY.
Financial health
How did ARS Pharmaceuticals financials performed over time
ARS Pharmaceuticals's quick ratio has plunged by 83% YoY and by 25% from the previous quarter
The company's current ratio has shrunk by 82% YoY and by 23% QoQ
ARS Pharmaceuticals's debt is 70% less than its equity
ARS Pharmaceuticals's equity has decreased by 11% from the previous quarter but it has increased by 2.3% YoY
The company's debt to equity rose by 11% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.